Cost-effectiveness and impact on infections and associated antimicrobial resistance of 20-valent pneumococcal conjugate vaccine in US children previously immunized with PCV13.

Autor:	Rozenbaum MH; Pfizer Inc., Collegeville, PA, USA., Huang L; Pfizer Inc., Collegeville, PA, USA., Cane A; Pfizer Inc., Collegeville, PA, USA., Arguedas A; Pfizer Inc., Collegeville, PA, USA., Chapman R; Evidera, London, UK., Dillon-Murphy D; Evidera, London, UK., Tort MJ; Pfizer Inc., Collegeville, PA, USA., Snow V; Pfizer Inc., Collegeville, PA, USA., Chilson E; Pfizer Inc., Collegeville, PA, USA., Farkouh R; Pfizer Inc., Collegeville, PA, USA.
Jazyk:	angličtina
Zdroj:	Journal of medical economics [J Med Econ] 2024 Jan-Dec; Vol. 27 (1), pp. 644-652. Date of Electronic Publication: 2024 Apr 19.
DOI:	10.1080/13696998.2024.2339638
Abstrakt:	Aim: The US Food and Drug Administration approved the 20-valent pneumococcal conjugate vaccine (PCV20) to prevent pneumococcal disease. In the context of routine PCV20 vaccination, we evaluated the cost-effectiveness and public health and economic impact of a PCV20 catch-up program and estimated the number of antibiotic prescriptions and antibiotic-resistant infections averted. Materials and Methods: A population-based, multi-cohort, decision-analytic Markov model was developed using parameters consistent with previous PCV20 cost-effectiveness analyses. In the intervention arm, children aged 14-59 months who previously completed PCV13 vaccination received a supplemental dose of PCV20. In the comparator arm, no catch-up PCV20 dose was given. The direct and indirect benefits of vaccination were captured over a 10-year time horizon. Results: A PCV20 catch-up program would prevent 5,469 invasive pneumococcal disease cases, 50,286 hospitalized pneumonia cases, 218,240 outpatient pneumonia cases, 582,302 otitis media cases, and 1,800 deaths, representing a net gain of 30,014 life years and 55,583 quality-adjusted life years. Furthermore, 720,938 antibiotic prescriptions and 256,889 antibiotic-resistant infections would be averted. A catch-up program would result in cost savings of $800 million. These results were robust to sensitivity and scenario analyses. Conclusions: A PCV20 catch-up program could prevent pneumococcal infections, antibiotic prescriptions, and antimicrobial-resistant infections and would be cost-saving in the US.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu